ARTICLE | Clinical News
Atrix completes Phase III Leuprogel study
March 23, 2001 8:00 AM UTC
ATRX completed enrollment of 89 patients in a Phase III trial of its Leuprogel leuprolide 4-month, 30 mg, subcutaneous depot injection to treat advanced prostate cancer. The product is a gonadotropin-...